Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation

dc.contributor.authorGaikwad, Anil Bhanudas
dc.date.accessioned2023-12-27T06:56:44Z
dc.date.available2023-12-27T06:56:44Z
dc.date.issued2023-11
dc.description.abstractTargeting Toll-like receptor 4 (TLR4) and Angiotensin II type 1 receptor (AT1R) could provide renoprotection during acute kidney injury (AKI) mainly by regulating inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Phloretin (TLR4 inhibitor) as an add-on therapy to losartan (AT1R inhibitor) could provide more therapeutic benefits against AKI under diabetic condition. We aimed to study the effect of phloretin as an add-on therapy to losartan against AKI under diabetic condition.en_US
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0024320523007300
dc.identifier.urihttp://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13528
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.subjectPharmacyen_US
dc.subjectInflammationen_US
dc.subjectPhloretinen_US
dc.subjectToll-like receptor-4 (TLR4)en_US
dc.subjectDiabetesen_US
dc.subjectAcute Kidney Injury (AKI)en_US
dc.titlePhloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammationen_US
dc.typeArticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: